SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): February 22, 2016
OptimizeRx
Corporation
(Exact name of registrant as specified in its charter)
Nevada |
|
000-53605 |
|
26-1265381 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
400
Water Street, Suite 200, Rochester, MI |
|
48307 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: 248-651-6568
|
|
|
|
(Former
name or former address, if changed since last report) |
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION
7 – Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure
On
February 22, 2016, we issued a press release concerning the appointment of William Febbo to the position of Chief Executive Officer.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The
information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
SECTION
9 – Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits
99.1 |
|
Press release, dated February 22, 2016 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OptimizeRx
Corporation |
|
|
Date:
February 22, 2016 |
/s/
Doug Baker |
|
Doug
Baker |
|
Chief
Financial Officer |
3
Exhibit 99.1
OptimizeRx
Corporation Appoints William J. Febbo as CEO
ROCHESTER,
MI. – February 22, 2016 – OptimizeRx Corp. (OTCQB: OPRX), a software company whose premier content-delivery platform
enables pharmaceutical companies to provide on-demand patient-savings and support services right at point of prescribe, has appointed
William J. Febbo as chief executive officer. Febbo succeeds David Harrell, who will continue to serve as chairman of the Board.
Febbo
brings to OptimizeRx more than 18 years of experience in building and managing health services and financial businesses. His career
includes strategic development, technology and product innovation, corporate finance, and M&A within a variety of leadership
roles.
“Will’s extensive leadership experience in
both technology and healthcare companies made him the ideal candidate to lead us through our next stage of growth,” said
Harrell. “In fact, he has already contributed important leadership when, as COO of Merriman Capital, he helped secure WPP's
investment via their operating company, greyhealth group (ghg), a leading provider of healthcare communications services.”
Febbo commented: “When I met Dave and his team, it
was clear they had the vision and passion to strengthen OptimizeRx’s market leadership in automating copay savings and product
support right within physicians’ electronic workflow. I helped lead the discussions for ghg to become a strategic investor,
given their domain expertise, client reach, and strong leadership team. This team includes their CEO, Lynn Vos O’Connor,
who recently joined OptimizeRx’s board. Through this equity partnership, we plan to navigate OptimizeRx’s EHR eco-system
and its unique pathway between medical professionals and industry to grow more brands and services.”
OptimizeRx
has partnered with more than 20 of the largest pharmaceutical manufacturers in the world, including Pfizer, Lilly, Novartis, Sanofi,
Bayer and AstraZeneca. These companies have automated their copay savings and trial voucher programs using OptimizeRx’s
proprietary, on-demand, content delivery platform that reaches more than 250,000 healthcare providers through a network of over
350 electronic health records (EHRs).
OptimizeRx’s
automation of copay savings for brand drugs as a replacement of traditional drug samples represents a total projected addressable
market of more than $1 billion, with Surescripts forecast of more than 2 billion electronic prescriptions for 2016.
More
and more pharmaceutical and biotech companies are seeking higher return on investment on their marketing by working with innovative
digital platforms like OptimizeRx. The OptimizeRx platform has demonstrated an ROI of up to 12:1, according to independent studies
sponsored by pharmaceutical companies. These companies recognize the need for new ways to reach and support doctors who have less
and less time to spend with pharmaceutical sales representatives.
“Our
digital content-delivery platform is supporting the pharmaceutical industry’s shift from legacy paper prescription and sampling
to a digitally enabled relationship between patient and medical provider,” continued Febbo. “By connecting the fragmented
EHR environment, we deliver streamlined information to physicians and measurably improve the patient experience. We provide innovative
solutions to increase adherence to prescriptions, which represents a major obstacle to achieving improved health outcomes. OptimizeRx
has the capital to expand its sales and marketing efforts, as well as launch new products and services to drive revenue growth.”
Lynn Vos O’Connor, OptimizeRx’s director and
CEO of ghg, commented: “Will’s appointment comes at an opportune time with WPP and OptimizeRx developing new platforms
to deliver vital information to physicians and patients. Together, we plan to expand OptimizeRx’s point-of-care EHR promotional
network and service offerings.”
William
J. Febbo Bio
Febbo
is the founder and remains chairman of Plexuus, a payment processing platform for medical professionals with Sunshine Act-related
activities.
Febbo
was previously COO of Merriman Capital and CEO of Digital Capital Network (DCN), a wholly owned subsidiary of Merriman Holdings.
He led the launch of DCN, a technology solution that increases transparency, compliance and efficiency for stakeholders.
Prior
to Merriman, Febbo was CEO and co-founder of MedPanel, a provider of market intelligence and communications for the pharmaceutical,
biomedical and medical device industries, which was eventually acquired by MCF Corporation. MedPanel completed over 3,000 engagements
with the medical industry by engaging more than 300,000 medical professionals, allowing them to make better commercial and clinical
decisions.
Febbo
holds a Bachelor of Arts in International Studies from Dickinson College, in Pennsylvania.
About
OptimizeRx Corporation
OptimizeRx Corporation (OTCQB: OPRX) provides unique consumer and physician platforms to help patients better afford and
comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to
expand awareness, access and adherence to their medications.
The
company’s core product, SampleMD™, replaces drug samples with electronic trial vouchers and copay coupon savings,
which are added to an e-Prescription and electronically sent to the pharmacy. SampleMD is integrated within leading Electronic
Health Record (EHR) platforms, including Allscripts, Quest Diagnostics, Practice Fusion and Dr. First, reaching over 350 EHRs.
Important
Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as
amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make
an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements,
which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties
to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition
and other material risks.
Company
Contact:
OptimizeRx
Doug Baker
dbaker@samplemd.com
248-651-6568 x807
Investor
Relations Contact:
Liolios
Group
Ron
Both, Senior Managing Director
oprx@liolios.com
949-574-3860
3
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024